About PeproTech

PeproTech was established in 1988 by a group of scientists who decided to focus their efforts on the development and production of recombinant cytokines for life-science research. Today, PeproTech is a world leader in supplying high quality cytokine products including E. coli, insect, and mammalian cell-derived recombinant proteins, their monoclonal/polyclonal antibodies, ELISA development kits, and other cytokine-related reagents. These products are distributed worldwide through customer-service offices in the US, UK, France, Germany, Israel, Korea, China, Japan, Brazil, and Mexico. We plan to maintain the highly competitive price of our products and to expand their distribution to Australia, New Zealand, and other locations. To keep up with current research and growing demand we have recently expanded our production capabilities to include a 5000 sq. ft. animal-free manufacturing facility. A key component in keeping up with current scientific advancements has been our collaboration with researchers in both academia and industry who provide us with suggestions necessary to continuously expand our product pipeline. We encourage you to convey to us your particular research needs and promise to do our best to fulfill them.

Facts about PeproTech
  • Focus : Distributor
  • Industry : Biotechnology

Here you will find PeproTech Inc.

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous